ATRIUM THERAPEUTICS INC (RNA) Institutional Shareholders

ATRIUM THERAPEUTICS INC (RNA) is currently reported in institutional portfolios tracked by InsiderSet based on the latest available SEC Form 13F filings for the quarter ended June 30, 2026. The institutional investors covered on this page collectively reported approximately $192.62M in RNA holdings during the latest filing period.

Sessa Capital Im, L.P. is currently the largest disclosed institutional shareholder of RNA tracked by InsiderSet, reporting ownership valued at approximately $20.18M in its June 30, 2026 SEC Form 13F filing. Based on current market prices and the latest disclosed share count, the position is now estimated to be worth approximately $13.42M, representing an estimated loss of -33.46% since the filing period.

The top 10 institutional shareholders tracked on this page collectively account for approximately 54% of the total disclosed RNA value among the investors covered in this analysis. Major shareholders include Sessa Capital Im, L.P., Price T Rowe Associates Inc, Blackrock, Inc., and several other long-term asset managers with concentrated positions in ATRIUM THERAPEUTICS INC (RNA).

This page ranks the largest institutional RNA shareholders using publicly disclosed SEC Form 13F data, including reported values, estimated current holding values, portfolio allocation percentages, ownership concentration metrics, and historical holding changes across major hedge funds and investment firms.

Institutional Holders

147

Total Reported Value

$192.62M

Largest Holder

Sessa Capital Im, L.P.

Largest Position

$20.18M

Insider Transactions (90d)

0

Latest Filing Quarter

Q2 2026

New Institutional Positions

71

Funds Exiting Positions

0

NameInvestor/ManagerPortfolio %QuantityReported BalanceCurrent Estimated ValueGain/loss Since FilingEstimated Portfolio Performance
Sessa Capital Im, L.P.0.35%1,500,000$20,175,000$13,425,000-$6,750,000-33.46%
Price T Rowe Associates Inc0.00%1,472,984$19,813,000$13,183,207-$6,629,793-33.46%
Blackrock, Inc.0.00%1,447,476$19,468,551$12,954,910-$6,513,641-33.46%
Vanguard Capital Management Llc0.00%730,831$9,829,677$6,540,937-$3,288,740-33.46%
Crcm Lp5.67%641,539$8,628,700$5,741,774-$2,886,926-33.46%
Tig Advisors, Llc0.35%561,533$7,552,619$5,025,720-$2,526,899-33.46%
Geode Capital Management, Llc0.00%386,929$5,205,392$3,463,015-$1,742,377-33.47%
Two Sigma Investments, Lp0.00%345,481$4,646,719$3,092,055-$1,554,664-33.46%
Goldman Sachs Group Inc0.00%310,341$4,174,086$2,777,552-$1,396,534-33.46%
683 Capital Management, Llc0.37%300,000$4,035,000$2,685,000-$1,350,000-33.46%
State Street Corp0.00%271,762$3,655,199$2,432,270-$1,222,929-33.46%
Arbiter Partners Capital ManagementPaul Isaac1.88%261,288$3,514,324$2,338,528-$1,175,796-33.46%
Cantor Fitzgerald, L. P.0.07%256,917$3,455,534$2,299,407-$1,156,127-33.46%
Slotnik Capital, Llc0.89%237,637$3,196,218$2,126,851-$1,069,367-33.46%
Weiss Asset Management Lp0.03%219,730$2,955,368$1,966,583-$988,785-33.46%
Millennium Management Llc0.00%200,559$2,697,519$1,795,003-$902,516-33.46%
Schonfeld Strategic Advisors Llc0.01%199,158$2,678,673$1,782,464-$896,209-33.46%
Aqr Capital Management Llc0.00%172,235$2,316,561$1,541,503-$775,058-33.46%
Nexpoint Asset Management, L.P.0.13%150,025$2,017,836$1,342,724-$675,112-33.46%
Polar Asset Management Partners Inc.0.04%150,000$2,017,500$1,342,500-$675,000-33.46%
Squarepoint Ops Llc0.00%146,743$1,973,693$1,313,350-$660,343-33.46%
Bracebridge Capital, Llc0.41%139,239$1,872,765$1,246,189-$626,576-33.46%
Janus Henderson Group Plc0.00%139,973$1,871,370$1,252,758-$618,612-33.06%
Nomura Holdings Inc0.01%137,394$1,847,949$1,229,676-$618,273-33.46%
Yakira Capital Management, Inc.0.53%133,047$1,789,482$1,190,771-$598,711-33.46%
Bank Of America Corp0.00%132,833$1,786,603$1,188,855-$597,748-33.46%
Charles Schwab Investment Management Inc0.00%130,217$1,751,419$1,165,442-$585,977-33.46%
Tudor Investment Corp Et Al0.01%129,591$1,742,999$1,159,839-$583,160-33.46%
Dafna Capital Management Llc0.33%128,000$1,721,600$1,145,600-$576,000-33.46%
Creek Drive Management Group Llc1.06%127,600$1,716,220$1,142,020-$574,200-33.46%
Norges Bank0.00%126,575$1,702,434$1,132,846-$569,588-33.46%
Anson Funds Management Lp0.15%125,000$1,681,250$1,118,750-$562,500-33.46%
Northern Trust Corp0.00%119,781$1,611,055$1,072,040-$539,015-33.46%
Exoduspoint Capital Management, Lp0.01%117,275$1,577,349$1,049,611-$527,738-33.46%
Trium Capital Llp0.96%113,278$1,523,589$1,013,838-$509,751-33.46%
Td Asset Management Inc0.00%111,200$1,495,640$995,240-$500,400-33.46%
Vanguard Fiduciary Trust Co0.00%109,961$1,478,975$984,151-$494,824-33.46%
Jane Street Group, Llc0.00%109,810$1,476,945$982,799-$494,146-33.46%
Athos Capital Ltd0.52%107,965$1,452,000$966,287-$485,713-33.45%
Awm Investment Company, Inc.0.13%107,500$1,445,875$962,125-$483,750-33.46%
Balyasny Asset Management L.P.0.00%105,875$1,424,019$947,581-$476,438-33.46%
Marble Bar Asset Management Llp0.97%103,849$1,396,769$929,449-$467,320-33.46%
Vanguard Portfolio Management Llc0.00%101,195$1,361,073$905,695-$455,378-33.46%
Adage Capital Partners Gp, L.L.C.0.00%100,000$1,345,000$895,000-$450,000-33.46%
Bluecrest Capital Management Ltd0.06%100,000$1,345,000$895,000-$450,000-33.46%
Credit Industriel Et Commercial0.13%89,723$1,206,774$803,021-$403,753-33.46%
Groupe La Francaise0.01%80,273$1,079,672$718,443-$361,229-33.46%
Fil Ltd0.00%76,500$1,028,925$684,675-$344,250-33.46%
Caption Management, Llc0.04%75,277$1,012,476$673,729-$338,747-33.46%
Citadel Advisors Llc0.00%67,639$909,745$605,369-$304,376-33.46%
Showing 50 of 147

Frequently asked questions about RNA

  • Who owns the most RNA stock?

    The largest holders of RNA are typically major institutional investors such as asset managers and hedge funds reporting on Form 13F. The table above ranks tracked superinvestors by reported position size using the latest available filings for ATRIUM THERAPEUTICS INC (RNA).

  • Is RNA widely held by superinvestors?

    Many widely followed stocks like RNA appear across numerous superinvestor portfolios because of liquidity, index inclusion, and fundamentals. The holder count and table above show how broadly RNA is represented among the institutional managers we track.

  • What do “Current Estimated Value”, “Gain/loss Since Filing”, and “Estimated Portfolio Performance” mean?

    Current Estimated Value is reported share quantity from the latest 13F times our most recent split-adjusted U.S. session close. Gain/loss Since Filing is that estimate minus the reported 13F dollar value; Estimated Portfolio Performance is that difference as a percent of the reported value. Green means the estimate is above the filing value; red means below (not purchase cost). If many filers share the same implied filing price per share, the performance % may match across rows. These are not official fund marks or live quotes.